Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3765774012 | Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3765775013 | Dextromethorphan hydrobromide 30 mg and guaifenesin 600 mg prolonged-release oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Dextromethorphan hydrobromide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator value | en | false | Inferred relationship | Some | 1 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator value | 600 | false | Inferred relationship | Some | 2 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator value | en | false | Inferred relationship | Some | 2 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has manufactured dose form | Prolonged-release oral tablet | true | Inferred relationship | Some | ||
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Guaifenesin | true | Inferred relationship | Some | 2 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has precise active ingredient | Dextromethorphan hydrobromide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator value | 30 | false | Inferred relationship | Some | 1 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has precise active ingredient | Guaifenesin | true | Inferred relationship | Some | 2 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Count of base of active ingredient | to | false | Inferred relationship | Some | ||
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Is a | Product containing only dextromethorphan and guaifenesin in oral dose form (medicinal product form) | true | Inferred relationship | Some | ||
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Plays role | Expectorant therapeutic role | true | Inferred relationship | Some | ||
| Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) | Plays role | Antitussive therapeutic role (role) | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Description inactivation indicator reference set
FHIR